Sophia Trujillo has blood drawn from her mediport at Advocate Children's Hospital in Park Ridge, Illinois, September 25, 2015. Trujillo has aplastic anemia and needs a bone marrow transplant but with her multi-racial background of Filipino, Spanish, Irish and Italian, the search for her match has been difficult. REUTERS/Jim Young TPX IMAGES OF THE DAY

Aastrom Biosciences Research Associate Judith Schmitt holds a centrifuge tube containing the harvested product ixmyelocel-T in the laboratory at their headquarters in Ann Arbor, Michigan November 29, 2011. Aastrom BioSciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. We're actually developing products now," said Tim Mayleben, chief executive of Aastrom Biosciences Inc, which is using cells derived from patients' own bone marrow to develop treatments for cardiovascular disease. Photo taken November 29, 2011. To match Insight STEMCELLS/ REUTERS/Rebecca Cook (UNITED STATES - Tags: BUSINESS SCIENCE TECHNOLOGY HEALTH)

Aastrom Biosciences Research Associate Judith Schmitt removes tissue culture and harvest solution from a centrifuge tube in the laboratory at their headquarters in Ann Arbor, Michigan November 29, 2011. Aastrom BioSciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. We're actually developing products now," said Tim Mayleben, chief executive of Aastrom Biosciences Inc, which is using cells derived from patients' own bone marrow to develop treatments for cardiovascular disease. Photo taken November 29, 2011. To match Insight STEMCELLS/ REUTERS/Rebecca Cook (UNITED STATES - Tags: BUSINESS SCIENCE TECHNOLOGY HEALTH)

Aastrom Biosciences Research Associate Judith Schmitt works with harvested ixmyelocel-T product in centrifuge tubes in the laboratory at their headquarters in Ann Arbor, Michigan November 29, 2011. Aastrom BioSciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. We're actually developing products now," said Tim Mayleben, chief executive of Aastrom Biosciences Inc, which is using cells derived from patients' own bone marrow to develop treatments for cardiovascular disease. Photo taken November 29, 2011. To match Insight STEMCELLS/ REUTERS/Rebecca Cook (UNITED STATES - Tags: BUSINESS SCIENCE TECHNOLOGY HEALTH)

Aastrom Biosciences Research Associate Judith Schmitt holds up harvested ixmyelocel-T product and solution in centrifuge tubes at their headquarters in Ann Arbor, Michigan November 29, 2011. Aastrom BioSciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. We're actually developing products now," said Tim Mayleben, chief executive of Aastrom Biosciences Inc, which is using cells derived from patients' own bone marrow to develop treatments for cardiovascular disease. Photo taken November 29, 2011. To match Insight STEMCELLS/ REUTERS/Rebecca Cook (UNITED STATES - Tags: BUSINESS SCIENCE TECHNOLOGY HEALTH)

Aastrom Biosciences Research Associate Judith Schmitt views harvested ixmyelocel-T product through a microscope in the laboratory at their headquarters in Ann Arbor, Michigan November 29, 2011. Aastrom BioSciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. We're actually developing products now," said Tim Mayleben, chief executive of Aastrom Biosciences Inc, which is using cells derived from patients' own bone marrow to develop treatments for cardiovascular disease. Photo taken November 29, 2011. To match Insight STEMCELLS/ REUTERS/Rebecca Cook (UNITED STATES - Tags: BUSINESS SCIENCE TECHNOLOGY HEALTH)

The logo of Aastrom Biosciences Inc is seen on an incubator in a laboratory at their headquarters in Ann Arbor, Michigan November 29, 2011. Aastrom BioSciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. We're actually developing products now," said Tim Mayleben, chief executive of Aastrom Biosciences Inc, which is using cells derived from patients' own bone marrow to develop treatments for cardiovascular disease. Photo taken November 29, 2011. To match Insight STEMCELLS/ REUTERS/Rebecca Cook (UNITED STATES - Tags: BUSINESS SCIENCE TECHNOLOGY HEALTH LOGO)

An Aastrom Biosciences production assistant holds a 'for research only' product bag containing the company's cell product ixmyelocel-T in the clean room laboratory at their headquarters in Ann Arbor, Michigan November 29, 2011. Aastrom BioSciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. We're actually developing products now," said Tim Mayleben, chief executive of Aastrom Biosciences Inc, which is using cells derived from patients' own bone marrow to develop treatments for cardiovascular disease. Photo taken November 29, 2011. To match Insight STEMCELLS/ REUTERS/Rebecca Cook (UNITED STATES - Tags: BUSINESS SCIENCE TECHNOLOGY HEALTH)

An Aastrom Biosciences production assistant holds a 'for research only' product bag containing the company's cell product ixmyelocel-T in the clean room laboratory at their headquarters in Ann Arbor, Michigan November 29, 2011. Aastrom BioSciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. We're actually developing products now," said Tim Mayleben, chief executive of Aastrom Biosciences Inc, which is using cells derived from patients' own bone marrow to develop treatments for cardiovascular disease. Photo taken November 29, 2011. To match Insight STEMCELLS/ REUTERS/Rebecca Cook (UNITED STATES - Tags: BUSINESS SCIENCE TECHNOLOGY HEALTH)

Aastrom Biosciences production assistant Mary Cheeramvelil works at 'priming' cell cassettes for incubation in the clean room laboratory at their headquarters in Ann Arbor, Michigan November 29, 2011. Aastrom BioSciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. We're actually developing products now," said Tim Mayleben, chief executive of Aastrom Biosciences Inc, which is using cells derived from patients' own bone marrow to develop treatments for cardiovascular disease. Photo taken November 29, 2011. To match Insight STEMCELLS/ REUTERS/Rebecca Cook (UNITED STATES - Tags: BUSINESS SCIENCE TECHNOLOGY HEALTH)

Aastrom Biosciences production assistant Marlo Ives places a bag of 'Base Medium' into an automated cell processing system in the clean room laboratory at their headquarters in Ann Arbor, Michigan November 29, 2011. Aastrom BioSciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. We're actually developing products now," said Tim Mayleben, chief executive of Aastrom Biosciences Inc, which is using cells derived from patients' own bone marrow to develop treatments for cardiovascular disease. Photo taken November 29, 2011. To match Insight STEMCELLS/ REUTERS/Rebecca Cook (UNITED STATES - Tags: BUSINESS SCIENCE TECHNOLOGY HEALTH)

Aastrom Biosciences production assistant Marlo Ives places a bag of 'Base Medium' into an automated cell processing system in the clean room laboratory at their headquarters in Ann Arbor, Michigan November 29, 2011. Aastrom BioSciences Inc recently presented promising results from a mid-stage trial of its treatment for patients with critical limb ischemia, a disease in which blood flow to the extremities is restricted, at the American Heart Association's annual meeting. We're actually developing products now," said Tim Mayleben, chief executive of Aastrom Biosciences Inc, which is using cells derived from patients' own bone marrow to develop treatments for cardiovascular disease. Photo taken November 29, 2011. To match Insight STEMCELLS/ REUTERS/Rebecca Cook (UNITED STATES - Tags: BUSINESS HEALTH SCIENCE TECHNOLOGY)

A nurse assists a man donating blood at a blood drive of the German red cross (DRK) in Berlin, June 6, 2011. German hospitals are struggling to cope with the flood of E.coli victims, as scientists remain puzzled by the deadly bug that has killed 22 and sickened 2,200 people across Europe. Hospitals in the northern port city of Hamburg, the epicentre of the outbreak that began three weeks ago,have been moving out patients with less serious illnesses to handle the surge of people stricken by the rare and virulent bacteria. REUTERS/Fabrizio Bensch (GERMANYPOLITICS - Tags: HEALTH) POLITICS)

Ten-month-old Kazakh boy Arman, suffering from anaemia and lung sickness, sleeps next to his mother, Ummet, in a hospital in Aralsk, south-western Kazakhstan April 18, 2005. Once the world's fourth largest lake, the Aral has shrunk so much that it has now split into two separate bodies of water. The United Nations Development Programme (UNDP) has been running an Aral Sea Programme since 1995, focusing mainly on water resources management, small business development, humanitarian assistance and a social and health programme as the ecological disaster of the dying sea has brought about a host of associated health problems. REUTERS/Shamil Zhumatov SZH/DY